Onconetix, Inc.

As of June 30, 2026, Onconetix, Inc. carries a market capitalization of 4.29M, placing it among publicly traded companies globally. Its enterprise value stands at -1.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Onconetix, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Onconetix, Inc. has 3.79M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.03, and the price-to-book ratio stands at 0.32.

As of June 30, 2026, Onconetix, Inc. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.39, indicating moderate leverage, while an interest coverage ratio of -52.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Onconetix, Inc. posted a negative return on equity (ROE) of -105.23, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -57.37, reflecting losses generated across the asset base. The company generates approximately 83,332.13 in revenue per employee across its workforce of 7.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.70 indicates how many times Onconetix, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Onconetix, Inc. recorded 525.00 in income tax expense. The company reported a pretax loss of -10.20M and -10.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Onconetix, Inc.'s stock has declined approximately 99.76% over the past 52 weeks. The 50-day moving average sits at 0.69, while the 200-day moving average is 16.36.

Over the twelve months ended June 30, 2026, Onconetix, Inc. generated 645,824.00 in revenue and converted that into -10.20M in net income, yielding earnings per share of -17.25. EBITDA reached -16.29M, while operating income came in at -7.69M.

As of June 30, 2026, Onconetix, Inc. holds 5.94M in cash and equivalents against 187,128.00 in total debt, resulting in a net debt position of -5.79M. Total book value stands at 13.47M, with working capital of 3.57M providing operational flexibility.

Onconetix, Inc. produced -10.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -10.31M - equivalent to -17.43 per share.

Over the twelve months ended June 30, 2026, Onconetix, Inc. posted a gross margin of 80.40, reflecting its pricing power and cost economics. The operating margin of -1,190.29 and net profit margin of -1,578.79 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1,542.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -364.79, meaning Onconetix, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Onconetix, Inc.'s most recent stock split took place on May 21, 2026 with a 10:1 split ratio.

As of June 30, 2026, Onconetix, Inc. has an Altman Z-Score of -30.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.